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Abstract
Background: Molecular methods to detect Leishmania parasites are considered specific and sensitive, but often
not applied in endemic areas of developing countries due to technical complexity. In the present study isothermal,
nucleic acid sequence based amplification (NASBA) was coupled to oligochromatography (OC) to develop a
simplified detection method for the diagnosis of leishmaniasis. NASBA-OC, detecting Leishmania RNA, was
evaluated using clinical samples from visceral leishmaniasis patients from East Africa (n = 30) and cutaneous
leishmaniasis from South America (n = 70) and appropriate control samples.
Results: Analytical sensitivity was 10 parasites/ml of spiked blood, and 1 parasite/ml of culture. Diagnostic
sensitivity of NASBA-OC was 93.3% (95% CI: 76.5%-98.8%) and specificity was 100% (95% CI: 91.1%-100%) on blood
samples, while sensitivity and specificity on skin biopsy samples was 98.6% (95% CI: 91.2%-99.9%) and 100% (95%
CI: 46.3%-100%), respectively.
Conclusion: The NASBA-OC format brings implementation of molecular diagnosis of leishmaniasis in resource poor
countries one step closer.
Background
The leishmaniases are a group of diseases with a broad
range of clinical manifestations. They are caused by sev-
eral species of the genus Leishmania, in the family Trypa-
nosomatidae. The World Health Organization considers
leishmaniasis as one of the most important neglected
parasitic diseases [1-3]. Leishmaniasis is endemic in 88
countries with 350 million people at risk of contracting
the disease. There is an estimated incidence of 1 to 1.5
million cases of cutaneous leishmaniasis (CL) and 500,
000 cases of visceral leishmaniasis (VL) primarily in
South America, East Africa and the Indian Subcontinent.
Early diagnosis of leishmaniasis is important in order
to avoid severe clinical manifestations to the patient
including mortality for VL patients. Routine diagnosis of
leishmaniasis relies on microscopic demonstration of
Leishmania amastigotes in aspirates from skin, lymph
nodes, bone marrow, liver or spleen and on culturing
parasites from these sites. However, aspirate sampling is
uncomfortable for the patient and the isolation of para-
sites by culturing is time-consuming, difficult and
expensive. A number of indirect serological tests such as
enzyme-linked immunosorbent assay (ELISA), rK39 dip-
sticks [4,5], direct agglutination test (DAT) [6] and the
fast agglutination screening test (FAST) [7] have been
developed for the sero-diagnosis of VL. Serology for CL
or for VL in immunocomprimised individuals may be
considered unreliable due to low or absent production
of specific antibodies [8]; although some evidence shows
successful serological diagnosis of VL in HIV co-infected
patients from Ethiopia with the DAT [9].
Sensitive and specific molecular diagnostic tests such as
polymerase chain reaction (PCR) have been developed for
the diagnosis of VL [10-13] and CL [14,15]. Furthermore,
nucleic acid sequence based assay (NASBA), an amplifi-
cation technique based on RNA detection has been
developed for the diagnosis of various infectious organ-
isms including mycobacteria [16], Plasmodium [17],
* Correspondence: h.schallig@kit.nl
2Koninklijk Instituut voor de Tropen (KIT)/Royal Tropical Institute, KIT
Biomedical Research, Amsterdam, the Netherlands
Mugasa et al. Parasites & Vectors 2010, 3:13
http://www.parasitesandvectors.com/content/3/1/13
© 2010 Mugasa et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Leishmania [18] and Trypanosoma brucei [19]. Despite
high sensitivity and specificity molecular diagnostic tests
are at present not ideal for field diagnosis as they employ
equipment that is not practical in field conditions and is
often expensive. In this study a simple single step dipstick
detection technique, Oligochromatography (OC), for the
detection of NASBA amplicons of the 18S RNA of Leish-
mania was evaluated. Previously, dipstick technology has
been developed in combination with PCR [20] and
NASBA [21] for the detection of T. brucei in the diagno-
sis of Human African Trypanosomiasis, leishmaniasis
[22,23] and identification of various old world species of
Leishmania [24]. In the present study the diagnostic per-
formance of a NASBA-OC assay using clinical samples
from various clinical presentations of leishmaniasis was
evaluated in a typical phase 1 diagnostic study where
proof of principle is assessed on clinical samples.
Results
All tests performed in the current study were valid since
there were no test failures observed. In case of an inva-
lid test result the control signal with the artificial Q
RNA was absent. A summary of the results is provided
in Table 1.
Analytical sensitivity and specificity of Leishmania NASBA-
OC
The analytical sensitivity of the developed Leishmania
NASBA-OC diagnostic test was assessed using serially
diluted parasites from culture and blood spiked with
L. donovani promastigotes. The NASBA-OC was able to
detect 1 parasite per ml (cultured parasites). The species
specificity was assessed on non target nucleic acids
(Mycobacterium tuberculosis, Plasmodium falciparum,
Brucella abortus, Salmonella typhi, T. b. gambiense, and
T. b. rhodesiense)a sw e l la sL. donovani.T h eN A S B A -
O Ca s s a yo n l yg a v eap o s i t i v er e s u l tf o rn u c l e i ca c i d s
from L. donovani culture; all other non target pathogens
nucleic acids gave negative results.
Clinical samples
In total, 50 blood samples from healthy controls and 30
blood samples from confirmed VL cases were analysed
in the Leishmania NASBA-OC test. All healthy control
samples were negative with the employed test. Twenty
eight of the parasitologically confirmed cases were posi-
tive with NASBA - OC. The sensitivity and specificity of
the NASBA-OC on blood samples was 93.3% (95%
CI: 76.5% - 98.8%) and 100% (95 CI: 91.1% - 100%),
respectively. The positive and negative predictive values
are 100% (95% CI: 85.0 - 100%) and 96.2% (95 CI: 85.7%
- 99.3%), respectively. The strength of agreement
between the NASBA-OC for VL and the combined
employed parasitological tests is considered to be very
good, with an observed agreement of 97.5% ( value =
0.946; 95% CI: 0.872 to 1.020)
Seventy five skin biopsies were tested of which 70
were from microscopically confirmed CL patients and 5
were from patients with other skin diseases. Of these, 69
samples tested positive for CL, and all the biopsies from
Table 1 Summary of the results of NASBA-OC testing of different clinical samples.
Clinical Sample Number of Samples NASBA-OC
positive
Number of Samples NASBA-OC
negative
Blood samples healthy controls from Sudan (n = 50) 0 50
Blood samples confirmed VL cases from Sudan (n = 30) 28 2
Skin biopsies of patients with other skin diseases from The
Netherlands (n = 5)
05
Skin biopsies of patients with confirmed CL from Suriname (n = 27) 27 0
Skin biopsies of patients with confirmed CL from Brazil (n = 43) 42 1
Sensitivity, specificity, positive (PPV) and negative predictive value (NPV) estimated at a 95% confidence interval (95% CI) of the NASBA-OC on
different clinical samples
NASBA-OC employed on blood samples
Sensitivity 93.3% (95% CI: 76.5% - 98.8%)
Specificity 100% (95 CI: 91.1% - 100%)
PPV 100% (95% CI: 85.0 - 100%)
NPV 96.2% (95 CI: 85.7% - 99.3%)
NASBA-OC employed on skin biopsies
Sensitivity 98.6% (95% CI: 91.2% - 99.9%)
Specificity 100% (95% CI: 46.3% - 100%)
PPV 100% (95% CI: 93.4% - 100%)
NPV 83.3% (95% CI: 36.5% - 99.1%)
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a CL patient (from Brazil) tested negative. The sensitiv-
ity and specificity of the NASBA-OC was 98.6% (95%
CI: 91.2% - 99.9%) and 100% (95% CI: 46.3% - 100%),
respectively. The NASBA-OC positive and negative pre-
dictive values are 100% (95% CI: 93.4% - 100%) and
83.3% (95% CI: 36.5% - 99.1%) respectively for the skin
biopsy samples. There was also a very good agreement
between microscopy and NASBA-OC with observed
agreement = 98.7% of the observations;  value = 0.902
(95% CI: 0.711 - 1.093) on the skin biopsy samples.
The combined agreement between NASBA-OC for
leishmaniasis and the employed diagnostic tests for
cutaneous and visceral leishmaniasis is 98.1%,  value =
0.958 (95% CI: 0.911 - 1.005)
Discussion
Over the last decade diagnostic tests based on molecular
biology techniques have proven to be more sensitive and
specific than the classical methods and thus case finding
has greatly improved using these techniques [25]; how-
ever, implementation of these tools may be difficult for
logistical, economic and technical reasons. Among the
molecular techniques that have been developed for
the diagnosis of leishmaniasis are PCR and NASBA. Here
we combine NASBA with Oligochromatographic tech-
nology to produce a diagnostic test that may be suitable
for implementation in the developing world. The
NASBA-OC assay developed in this study is based on the
18S rRNA gene sequence, and this target has been found
to be highly efficient for the diagnosis of leishmaniasis
from human clinical material [11,13]. The assay can be
used to detect any leishmaniasis causing species, since
the target sequence is common in all members of genus
Leishmania; speciation, which maybe important for treat-
ment considerations, can not be made here.
The analytical sensitivity of the NASBA-OC test for
leishmaniasis employed in this study, using both the cul-
tured parasites and spiked blood, was 1 and 10 parasites
per ml respectively which is slightly more sensitive than
that achieved in earlier studies [18,26]. A PCR-OC test for
the detection of leishmaniasis reached a sensitivity of
approximately 5 parasites/ml blood [23]. In contrast, Laur-
ent et al [24], used the OC dipstick to detect PCR products
of Leishmania but achieved a 10 times lower sensitivity of
14 parasites per μl of blood. However, this study targeted
a different gene, namely the cysteine proteinase B gene.
In the present study, blood samples of parasitologically
confirmed VL patients were used for the detection of
Leishmania. The sensitivity of the NASBA-OC on blood
samples from VL patients (>90%) is better compared to
PCR studies carried out earlier in Sudan [11] where sen-
sitivity was persistently lower (around 70%). This indi-
cates an advantage of NASBA-OC over conventional
PCR, especially in Sudan, where parasitaemia in general
is reported to be low [27].
A number of molecular tests have also been developed
for the diagnosis of CL. To this end, Bensoussan et al.
[14] compared three PCR assays used in the diagnosis of
CL; the spliced leader mini-exon PCR had the lowest
sensitivity of only, 53.8%, the rRNA gene internal tran-
scribed spacer 1 (ITS1) PCR had 91.0% sensitivity while
the kinetoplast DNA (kDNA) PCR achieved the highest
sensitivity (98.7%) which is comparable to 98.6% sensi-
tivity achieved in this study for CL. Recently, Deborg-
graeve et al. [23] developed a PCR-OC based on the 18S
rDNA gene for the diagnosis of leishmaniasis and was
able to diagnose 91.7% patients with cutaneous leishma-
niasis using skin biopsies compared to 98.6% sensitivity
found with NASBA-OC in the current study.
Previously, this NASBA amplification assay was used
in combination with electro-chemiluminescence (ECL)
for the detection of NASBA products. This method is
more complex, labour-intensive and requires sophisti-
cated equipment [18]. The sensitivity and the specificity
of the NASBA using ECL detection were comparable
with the results obtained in this study. Simplification of
the detection method, therefore, does not compromise
the accuracy of the NASBA as a diagnostic tool.
Furthermore, the oligochromatographic dipstick is sim-
pler, faster and more user friendly and better suited for
field use than the ECL detection method. Espinosa et al.
[22] performed PCR combined with OC in the Peruvian
j u n g l ea n dc o n s i d e r e dt h et i m er e d u c t i o na c h i e v e da
major advantage over conventional diagnostic methods
and predict possible implementation of the technology
in low-level-equipped laboratories.
A common downside of the technique described in this
study is contamination that may arise during the proce-
dure of NASBA, leading to false positive results. Although
contamination should be avoided in any other molecular
diagnostic tests, the concern is more imperative in
NASBA since the test is very sensitive and can amplify
such small amounts of nucleic acid compared to other
tests, including PCR. To avoid sample contamination the
NASBA enzymes that are responsible for amplification are
added to the reaction mixture in a special designated
room that is considered to be free of amplicons.
Conclusion
The current paper describes the development of a highly
sensitive and specific molecular detection method for
both cutaneous and visceral leishmaniasis based on an
isothermal amplification method and a simple read-out
system. The next step will be to subject the developed
assay to rigorous field testing to establish its diagnostic
value under resource-poor conditions with clinically sus-
pected patients.
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Cultured parasites
Promastigotes of L. donovani (MHOM/SD/68/1S) were
cultured in vitro as previously described [7] and the
parasites were reconstituted into 10
6 parasites per
ml aliquots in phosphate buffered saline (PBS). Ten-
fold serial dilutions of the culture were made (10
5,1 0
4,
10
3,1 0
2,1 0
1, and 1 parasites per ml) in triplicate. Simi-
larly, the same serial dilutions of parasites were used to
seed EDTA-supplemented blood from a non-endemic
healthy volunteer with the same parasite numbers.
Nucleic acid from other cultured pathogens, i.e.,
Mycobacterium tuberculosis, Plasmodium falciparum,
Brucella abortus, Salmonella typhi, T. b. gambiense, and
T. b. rhodesiense, were obtained from other research
groups and included in this study to assess analytical
specificity of the NASBA-OC test
Clinical samples
Clinical samples obtained from different study locations
were used in the present study. All clinical material
from Sudan was subject to appropriate ethical clearance
from the Faculty of Medicine, University of Khartoum
and from the National Ethical Committee at the Federal
Ministry of Health Sudan.
Samples from Suriname were collected at the Depart-
ment of Dermatology, Academic Hospital Paramaribo
(Anton de Kom University of Suriname) and at the Der-
matological Service, Tourtonnelaan, Paramaribo. The
work performed in Suriname was reviewed and
approved by the Medical Ethical Committee of the Aca-
demic Medical Centre, Amsterdam, The Netherlands
(MEC 03/228). Sample collection in Brazil was at Fun-
dação de Medicina Tropical do Amazonas, Manaus, Bra-
zil and approved by the Brazilian National Review Board
of the Ministry of Health (Commissão Nacional de Ética
em Pesquisa Parecer no. 1142/2005).
Written informed consent was obtained from study
cases before clinical samples for research purpose were
collected.
Clinical samples of visceral leishmaniasis patients
Blood samples (n = 30) from Sudanese visceral leishma-
niasis patients, parasitologically confirmed by micro-
scopic examination of bone marrow aspirates, were used
in the present study. The samples were processed in the
Leishmaniasis Research Laboratory of Soba Teaching
Hospital (Khartoum University) and all were found posi-
tive for Leishmania
Clinical samples from cutaneous leishmaniasis patients
Skin biopsies from confirmed CL patients were collected
from Brazil (n = 43) and Suriname (n = 27). Parasitologi-
cal diagnosis was achieved by direct microscopic detec-
tion of Leishmania amastigotes in Giemsa stained skin
smears for patients with CL. A single skin biopsy (2-mm
in diameter) was collected under local anesthesia (xylo-
caine) with a sterile disposable skin biopsy puncher from
the active edge of the lesion according to WHO recom-
mendations [3]. Species identification was performed at
Royal Tropical Institute, KIT Biomedical Research,
Amsterdam, The Netherlands, using standard PCR-RFLP
techniques [28]. The samples from Suriname all con-
tained L. braziliensis guyanensis; 37 samples from Brazil
contained this parasite also, 5 Brazilian samples had
L. b. braziliensis and one was typed as L. amazonensis
Endemic controls
Blood was also collected from 50 healthy individuals
without clinical signs or complaints associated with
leishmaniasis from Sudan to serve as endemic controls.
In addition, skin biopsies were collected from indivi-
duals (n = 5) with lesions due to other conditions than
cutaneous leishmaniasis [18]: ulcerative pyloderma
(n = 2), folliculitis (n = 1), dermatitis (n = 1) and sarcoi-
dosis (n = 1). These individuals visited the Dermatology
Outpatient clinic of the Academic Medical Centre
(Amsterdam, The Netherlands) and are non-endemic
patients.
Extraction of nucleic acid from clinical samples
Skin biopsies (2 mm in diameter) from lesions of CL
patients were mixed with 950 μl L6 lysis buffer (50 mM
Tris HCl, 5 M GuSCN, 20 mM EDTA, 0,1% Triton-
X-100) and stored at -70°C.
Two hundred μl EDTA blood from VL patients was
mixed with 1200 μl of L6 lysis buffer and 40 μl of silica
and centrifuged. The sediment was kept at -20°C. RNA
and DNA were extracted from the samples as described
earlier with the Boom method [29].
NASBA
The NASBA employed in this study targets a 170-bp
region in the 18S rRNA, and was performed using the
Nuclisense BasicKit (BioMérieux) for amplification fol-
lowing the procedures published previously [18]. The
primers and probes employed in the amplification are
presented in the Appendix. The NASBA reaction com-
prised three enzymes needed for replication; i.e. AMV-
RT, RNase H and T7 RNA polymerase, which are added
to the reaction mixture in an amplicon free room to
reduce the change of sample contamination, and was
performed in a 10 μl total reaction volume at a final
KCl concentration of 70 mM containing 0.416 μMo f
each primer
Artificial constructed in vitro RNA, referred to as
QR N A ,( 1 0
6 molecules per reaction) derived via site-
directed mutagenesis, was added to the NASBA mix and
serves as an internal amplification control (Appendix).
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The reaction mixture was incubated in a 0.5 ml tube
with 2.5 μl RNA extract at 65°C for 2 minutes and then
at 41°C for 2 minutes. The NASBA enzymes were sub-
sequently added and isothermal amplification took place
for 90 minutes at 41°C in a heat block. All samples were
tested 3 times for reproducibility. Amplified RNA pro-
duct was detected using the oligochromatography detec-
tion method.
Detection by oligochromatography
Oligochromatographic (OC) detection of NASBA pro-
ducts (for more details on the OC test see: http://www.
corisbio.com/public/product/documents/ProductFile-
Leishmania.pdf was completed in an assay tube pre-
heated at 55°C. 4 μl of NASBA amplification product
was mixed with 76 μl of migration buffer, preheated at
55°C, in an assay tube and subsequently an OC dipstick
was dipped into the mixture. The assay tube was sealed
with a cap and incubated at 55°C for 10 minutes, after
which both sides of the OC dipsticks were read [20-24].
Statistical analysis
The sensitivity and specificity of the Leishmania
NASBA-OC test were calculated using the formulas:
TP×100/(TP+FN) and TN×100/(TN+FP) respectively,
where TP, TN, FP and FN represent; true positives, true
negatives, false positives and false negatives. The positive
and negative predictive values were calculated by analy-
sis of 2 × 2 contingency tables. All calculations were
estimated at a 95% confidence interval (95% CI).
Furthermore, the degree of agreement between the
evaluated tests was determined by calculating Kappa ()
values with 95% confidence intervals using Epi-info ver-
sion 6. Kappa values express the agreement between
tests that is beyond chance; a  value of 0.60 to 0.80
represents a substantial agreement beyond chance,
whereas a  value of > 0.80 represents almost perfect
agreement beyond chance.
Appendix
Primers and probe sequences employed in the Leishma-
nia 18S NASBA assay and oligochromatography
18S Leishmania primers sequences
Leish 18S F GEN
1.5’-GATGCAAGGTCGCATAT-
GAGCCAAAGTGTGGAGATCGAAG -3’
Leish 18S T7 R
25’-AATTCTAATACGACTCACTA-
TAGGGAGAAGGGCCGGTAAAGGCCGAATAG -3’
18S Leishmania probe sequences
Capture probe NASBA Leish Wt: 5’-AGACCATTG-
TAGTCCACACTGC-3’ -biotin
Capture probe NASBA Leish Q: 5’-CTTAGGTCCAC-
TAAGGTACC-3’ -biotin
Detection probe NASBA Leish: 5’-G A T G -
CAAGGTCGCATATGAG-3’
Leish-QRNA:
5’CCAAAGTGTGGA GATCGAAGATGATTAGCT-
TAGGTCCACTAAG GTACCCAAACGATGACACCCA
TGAAT
TGGGGATCTTATGGGCCGGCCTGCGGCAGGGT
TTACCCTGTGTCCAGCA
CCGCGCCCGCTTTTACCANCTTACGTATCCTTT-
CTATTCGGCCTTTACCGGCC 3’
1T h es e q u e n c ei nb o l di sag e n e r i ct a i le n a b l i n gt h e
hybridization of the NASBA product by the detection
probe.
2The region which is presented in italics is the T7
promoter sequence.
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